The Consequences of E-Cigarette Taxation on Youth Smoking

Oct.06.2022
The Consequences of E-Cigarette Taxation on Youth Smoking
The proposed Senate bill aimed to prevent youth smoking and vaping, but was vetoed due to high e-cigarette taxation.

Senate Bill 45 was originally proposed by Senator Gary Stevens with the aim of preventing young people from smoking and vaping, but it was vetoed by Governor Dunleavy due to the proposed high tax rate on e-cigarettes. Dunleavy stated that it was not possible to separate tobacco age restrictions from the proposed taxation, leading to his decision to veto the bill.


Meanwhile, a recent study by Yale University professor Abigail Friedman and Georgia State University professor Michael Pesko confirms that taxing electronic cigarettes could lead to an increase in smoking rates, resulting in serious consequences.


The study, titled "Young People's Response to Taxation on Cigarettes and Electronic Nicotine Delivery Systems," examined the impact of increasing taxes on electronic cigarettes on the smoking behavior of young consumers aged 18 to 25. Consistent with expert arguments and predictions in the field, researchers found that while higher taxes on electronic cigarettes resulted in a decrease in usage, it also led to an increase in smoking rates.


The author reports that a $1 increase in the tax on e-cigarettes would significantly reduce daily use among young people, while recent smokers would also increase. The researchers ultimately concluded that "higher taxes on electronic nicotine delivery systems (ENDS) are associated with a decrease in ENDS use, but also with an increase in smoking rates among the 18-25 age group.


An article on Fee.Org highlights a well-known phenomenon called "substitution effect," where a decrease in product sales is often attributed to consumers switching to cheaper alternatives.


Statement:


This article is compiled from third-party information and is only for industry professionals to exchange and learn.


This article does not represent the viewpoint of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness and accuracy of the content. The translation of this article is solely for industry exchange and research purposes.


Due to limitations in the level of translation, the translated article may not fully express the intended meaning of the original text. Therefore, we advise readers to refer to the original article for accurate information.


2FIRSTS maintains complete alignment with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements and positions.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us to have the content removed.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Imperial Brands names John Rishton chair-designate, to take over as chair in December 2026
Imperial Brands names John Rishton chair-designate, to take over as chair in December 2026
Imperial Brands said in a statement on its website that John Rishton will join the board in July 2026 and assume the role of chair in December, succeeding current chair Thérèse Esperdy, who will retire at that time.
Jan.21 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
South Korea’s Seoul Gangnam District Installs “Separated Smoking Booths” , Splitting Cigarettes and Vapes
South Korea’s Seoul Gangnam District Installs “Separated Smoking Booths” , Splitting Cigarettes and Vapes
Seoul's Gangnam district introduces smoking booths on Tehran Road to combat public smoking and secondhand smoke issues.
Jan.23 by 2FIRSTS.ai
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
PMI says it submitted evidence to FDA panel backing ZYN bid for modified-risk status
Philip Morris International said it presented scientific evidence to the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee to support its ZYN nicotine pouches seeking a modified risk tobacco product designation, which would allow the company to communicate to adult smokers that switching completely to ZYN could reduce the risk of multiple smoking-related diseases.
Jan.26 by 2FIRSTS.ai
KT&G says lil reached about US$2.924 billion in cumulative sales and is expanding overseas
KT&G says lil reached about US$2.924 billion in cumulative sales and is expanding overseas
KT&G said its HNB brand lil has grown since launch, reporting KRW 7.8 billion (about US$5.304 million) in sales in 2017 and about KRW 4.3 trillion (about US$2.924 billion) in cumulative sales by last year’s third quarter, with KRW 5 trillion (about US$3.400 billion) described as within reach. KT&G said lil has entered more than 30 countries and supplies some products abroad via a partnership with PMI.
Jan.13 by 2FIRSTS.ai
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
Fifth Circuit Upholds FDA’s 2021 PMTA Rule, Citing Statutory Health-Study Requirements
A Fifth Circuit panel upheld the U.S. Food and Drug Administration’s 2021 final rule requiring companies seeking premarket authorization for new tobacco products to include information on health-risk investigations. In a published opinion, the court found FDA satisfied the Regulatory Flexibility Act’s procedural requirements and reasonably relied on the economic analysis from the 2016 “deeming rule” as a factual basis to certify limited impact on small businesses.
Feb.27 by 2FIRSTS.ai